Expression of selected molecular factors in two types of endometrial cancer

Abstract

Background. Endometrial cancers (EC) are a heterogeneous group of malignant neoplasms differing in etiology, clinical-pathological features and prognosis.Objectives. The aim of our study is to determine differences between the expression of selected molecular factors and find connections between them in order to isolate possible biomarkers influencing treatment options. Materials and methods.The investigated data involved archival histological preparations obtained from uterine EC samples taken from 137 patients, treated surgically between 2007 and 2014. The immunohistochemical Dako EnVision TM Flex+ method was applied.Results. The expression of ERβ, MLH1 and BRCA1 was lower in ECI than in ECII patients. ERα expression was higher in early Fédération internationale de gynécologie et d'obstétrique (FIGO) (IA) stages than in advanced (IB-IV) stages, while ERβ expression was significantly higher in advanced stages compared to stage IA and increased with grading. BRCA1 expression also increased with grading. In both type I and type II EC patients, ERα expression correlated with MYH9 and BRCA1, while ERβ expression correlated with BAP expression. High expression of BRCA1 correlated with several proteins: BAP, MYH9 and FAK. High BAP expression also correlated with high MYH9 expression. A correlation in the expression of these proteins was also demonstrated in the group consisting only of patients with ECI. A significant correlation was found between BAP expression and MYH9 among patients diagnosed with ECI. In the ECII group, no correlation was found between the tested proteins.Conclusions. The ECI and ECII patients differed in the studied molecular factors, mainly in terms of ER and BRCA1 expression. Changes in BRCA1 expression were linked to alterations in BAP expression, but were also associated with the proteins MYH9 and FAK.

Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer—An Immunohistochemical Assessment

“…In our study, we observed significantly higher PgR expression in endometroid-type EC than serous-type EC. Markowska et al noted similar results, with a higher expression of PgR in type I EC than type II EC [2]. The downregulated expression of PgR in seroustype EC may be connected with cell nuclei changes.…”

“…been previously calibrated using a computer program. The obtained surface area values were expressed in µm 2 Early malignant changes were absent in the women subjected to Aquafilling breast augmentation that was based on the E-cadherin and N-cadherin immunohistochemical expression [22].…”

“…Moreover, 1811 deaths caused by uterine corpus cancer were reported in 2020, which constitutes 3.98% of all cancer deaths reported in Poland that year [1]. One of the most common types of cancer in women in Poland and worldwide is endometrial cancer (EC) [2].…”

Construction and validation of a clinical risk model based on machine learning for screening characteristic factors of lymphovascular space invasion in endometrial cancer

“…EC is primarily classified into two types: I and II. Of these, type I EC is commonly found in obese women, is associated with hyperlipidemia and hyperestrogenism, and is estrogen-sensitive, with a slow course of disease and a good prognosis 2 . Type II EC progresses rapidly and is associated with a poor prognosis, but is not significantly related to estrogen.…”

Could Surgery Improve Survival in Patients with Advanced Endometrial Cancer?

“…Subdivision of endometrial cancer into two types is well recognized. This subdivision was based on the biological behavior and spread of the disease [4], but other new classifications are proposed based on molecular and genetics characterization [5] [6]. Type II endometrial cancer is managed similarly to high grade serous ovarian cancer [7].…”